Physicians stand to earn big money when signing up patients for drug trials. And lately, some of those trials have been ...

Press releases are posted on Independent.com as a free community service. April 24, 2025 (Santa Barbara, CA) The Nuclear Medicine Department at Ridley-Tree Cancer Center, now part of Sutter Health, ...

--Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. The move comes as Novartis’ second-quarter sales of $14 billion met Wall Street’s ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier ...

Policy, precision medicine, and new ways of delivering therapeutics were popular topics in 2025 among readers of ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s (NYSE:NVS) Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of ...

Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who ...

Highlights of the conference coverage from the 2025 European Society of Medical Oncology (ESMO) Congress included content on ...